Her kan du lese mer om Monaleesa 3 og Monaleesa 7 studien

  1. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019: DOI: 10.1056/NEJMoa1903765.
  2. Slamon DJ, Neven P, Chia S, et al. phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-2472.

 

 

NO2005267331
×

Medical Information Request

×

Ask Speakers